Roth Capital Has Bullish Forecast for TLSI Q3 Earnings

Key Points

• Roth Capital has improved its earnings outlook for TriSalus Life Sciences, raising the Q3 2025 earnings per share estimate from ($0.12) to ($0.10).
• TLSI stock opened at $4.55 and has a market capitalization of $172.17 million, with a P/E ratio of -3.86.
• TriSalus Life Sciences reported Q2 earnings of ($0.27) per share, missing expectations, but its revenue of $11.21 million exceeded analyst estimates.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Investment analysts at Roth Capital upped their Q3 2025 earnings estimates for TriSalus Life Sciences in a research report issued on Wednesday, August 13th. Roth Capital analyst J. Wittes now expects that the company will post earnings per share of ($0.10) for the quarter, up from their previous forecast of ($0.12). The consensus estimate for TriSalus Life Sciences' current full-year earnings is ($1.55) per share. Roth Capital also issued estimates for TriSalus Life Sciences' Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.77) EPS, FY2026 earnings at ($0.24) EPS and FY2027 earnings at $0.01 EPS.

TriSalus Life Sciences Price Performance

TLSI traded up $0.09 on Monday, reaching $5.05. 166,429 shares of the company's stock were exchanged, compared to its average volume of 94,954. The stock has a market cap of $191.09 million, a PE ratio of -4.28 and a beta of 0.48. TriSalus Life Sciences has a twelve month low of $3.42 and a twelve month high of $5.88. The stock's fifty day moving average price is $4.73 and its 200-day moving average price is $5.20.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The firm had revenue of $11.21 million for the quarter, compared to analyst estimates of $10.69 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On TriSalus Life Sciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Police & Firemen s Retirement System of New Jersey acquired a new position in TriSalus Life Sciences during the second quarter worth about $29,000. JPMorgan Chase & Co. boosted its position in TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company's stock worth $41,000 after acquiring an additional 7,519 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in TriSalus Life Sciences during the second quarter worth about $47,000. Charles Schwab Investment Management Inc. acquired a new position in TriSalus Life Sciences during the first quarter worth about $55,000. Finally, Renaissance Technologies LLC acquired a new position in TriSalus Life Sciences during the fourth quarter worth about $67,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.